Infused CD34+ cell dose predicts long-term survival in acute myelogenous leukemia patients who received allogeneic bone marrow transplantation from matched sibling donors in first complete remission

Biology of Blood and Marrow Transplantation

Volumn 11, Issue 2, 2005, Pages 122-128

  Lee, Se Hoon ^a   Lee, Mark H ^b   Lee, Je Hwan ^c   Min, Yoo Hong ^d   Lee, Kyoo Hyung ^c   Cheong, June Won ^d   Lee, Jeeyun ^a   Park, Keon Woo ^a   Kang, Jung Hun ^a   Kim, Kihyun ^a   Kim, Won Seog ^a   Jung, Chul Won ^a   Choi, Seong Jun ^c   Lee, Jung Hee ^c   Park, Keunchil ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b EAST CAROLINA UNIVERSITY   (United States)

^c University of Ulsan College of Medicine   (South Korea)

^d Yonsei University College of Medicine   (South Korea)

Author keywords

Acute myelogenous leukemia; Allogeneic BMT; CD34+ cell dose

Indexed keywords

CD34 ANTIGEN; CYCLOSPORIN A; METHOTREXATE;

ACUTE GRAFT REJECTION; ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; BLOOD DONOR; CANCER CLASSIFICATION; CANCER INCIDENCE; CANCER MORTALITY; CANCER PATIENT; CHRONIC GRAFT REJECTION; CONTROLLED STUDY; DATA ANALYSIS; DISEASE CLASSIFICATION; FEMALE; GRAFT VERSUS HOST REACTION; HLA MATCHING; HUMAN; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL; PREDICTION; PROGNOSIS; SIBLING; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTE; TREATMENT OUTCOME; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; ANTIGENS, CD34; BONE MARROW CELLS; BONE MARROW TRANSPLANTATION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; LEUKOCYTE COUNT; MALE; MIDDLE AGED; RECURRENCE; SIBLINGS; TISSUE DONORS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 19944433548     PISSN: 10838791     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbmt.2004.11.018     Document Type: Article

References (31)

1. R.J. O'Reilly Allogenic bone marrow transplantation: Current status and future directions Blood 62 1983 941-964
2. M.S. Tallman K.J. Kopecky D. Amos et al. Analysis of prognostic factors for the outcome of marrow transplantation or further chemotherapy for patients with acute nonlymphocytic leukemia in first remission J Clin Oncol 7 1989 326-337
3. P.B. McGlave R.J. Haake B.C. Bostrom et al. Allogeneic bone marrow transplantation for acute nonlymphocytic leukemia in first remission Blood 72 1988 1512-1517
4. S. Keating S. Suciu T. de Witte et al. Prognostic factors of patients with acute myeloid leukemia (AML) allografted in first complete remission: An analysis of the EORTC-GIMEMA AML 8A trial. The European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell' Adulto (GIMEMA) Leukemia Cooperative Bone Marrow Transplant 17 1996 993-1001
5. E. Jourdan D. Maraninchi J. Reiffers et al. Early allogeneic transplantation favorably influences the outcome of adult patients suffering from acute myeloid leukemia. Societe Francaise de Greffe de Moelle (SFGM) Bone Marrow Transplant 19 1997 875-881
6. R.P. Gale M.M. Horowitz R.S. Weiner et al. Impact of cytogenetic abnormalities on outcome of bone marrow transplants in acute myelogenous leukemia in first remission Bone Marrow Transplant 16 1995 203-208
7. A. Ferrant M. Labopin F. Frassoni et al. Karyotype in acute myeloblastic leukemia: Prognostic significance for bone marrow transplantation in first remission: A European Group for Blood and Marrow Transplantation study. Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT) Blood 90 1997 2931-2938
8. J.Y. Cahn M. Labopin J. Sierra et al. No impact of high-dose cytarabine on the outcome of patients transplanted for acute myeloblastic leukaemia in first remission. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT) Br J Haematol 110 2000 308-314
9. O. Ringden M. Labopin S. Tura et al. A comparison of busulphan versus total body irradiation combined with cyclophosphamide as conditioning for autograft or allograft bone marrow transplantation in patients with acute leukaemia. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT) Br J Haematol 93 1996 637-645
10. C.H. Weaver R.A. Clift H.J. Deeg et al. Effect of graft-versus-host disease prophylaxis on relapse in patients transplanted for acute myeloid leukemia Bone Marrow Transplant 14 1994 885-893
11. N. Schmitz A. Bacigalupo D. Hasenclever et al. Allogeneic bone marrow transplantation vs filgrastim-mobilised peripheral blood progenitor cell transplantation in patients with early leukaemia: First results of a randomised multicentre trial of the European Group for Blood and Marrow Transplantation Bone Marrow Transplant 21 1998 995-1003
12. W.I. Bensinger P.J. Martin B. Storer et al. Transplantation of bone marrow as compared with peripheral blood cells from HLA-identical relatives in patients with hematologic cancers N Engl J Med 344 2001 175-181
13. N.C. Gorin M. Labopin V. Rocha et al. European Cooperative Group for Blood and Marrow Transplantation Acute Leukemia Working Party. Marrow versus peripheral blood for geno-identical allogeneic stem cell transplantation in acute myelocytic leukemia: Influence of dose and stem cell source shows better outcome with rich marrow Blood 102 2003 3043-3051
14. R. Storb R.L. Prentice E.D. Thomas Marrow transplantation for treatment of aplastic anemia: An analysis of factors associated with graft rejection N Engl J Med 296 1997 61-66
15. M.M. Bortin R.P. Gale H.E. Kay et al. Bone marrow transplantation for acute myelogenous leukemia: Factors associated with early mortality JAMA 249 1983 1166-1175
16. O. Ringden B. Nilsson Death by graft-versus-host disease associated with HLA mismatch, high recipient age, low marrow cell dose, and splenectomy Transplantation 40 1985 39-44
17. J. Tollemar O. Ringden L. Bostrom et al. Variables predicting deep fungal infections in bone marrow transplant recipients Bone Marrow Transplant 4 1989 635-641
18. T. Paulin Importance of bone marrow cell dose in bone marrow transplantation Clin Transplant 6 1992 48-54
19. J. Sierra B. Storer J.A. Hansen et al. Transplantation of marrow cells from unrelated donors for treatment of high-risk acute leukemia: The effect of leukemic burden, donor HLA matching, and marrow cell dose Blood 89 1997 4226-4235
20. V. Rocha M. Labopin E. Gluckman et al. Acute Leukemia Working Party of the European Blood and Marrow Transplant Registry. Relevance of bone marrow cell dose on allogeneic transplantation outcomes for patients with acute myeloid leukemia in first complete remission: Results of a European survey J Clin Oncol 20 2002 4324-4330
21. D. Mavroudis E. Read M. Cottler-Fox et al. CD34+ cell dose predicts survival, posttransplant morbidity, and rate of hematologic recovery after allogeneic marrow transplants for hematologic malignancies Blood 88 1996 3223-3229
22. E. Bahceci E.J. Read S. Leitman et al. CD34+ cell dose predicts relapse and survival after T-cell-depleted HLA-identical haematopoietic stem cell transplantation (HSCT) for haematological malignancies Br J Haematol 108 2000 408-414
23. S. Kato H. Yabe M. Yasui et al. Allogeneic hematopoietic transplantation of CD34+ selected cells from an HLA haplo-identical related donor: A long-term follow-up of 135 patients and a comparison of stem cell source between the bone marrow and the peripheral blood Bone Marrow Transplant 26 2000 1281-1290
24. 6 CD34+ cells/kg be considered the minimum threshold? Bone Marrow Transplant 26 2000 489-496
25. H. Bittencourt V. Rocha S. Chevret et al. Association of CD34 cell dose with hematopoietic recovery, infections, and other outcomes after HLA-identical sibling bone marrow transplantation Blood 99 2002 2726-2733
26. O. Ringden A.J. Barrett M.J. Zhang et al. Decreased treatment failure in recipients of HLA-identical bone marrow or peripheral blood stem cell transplants with high CD34 cell doses Br J Haematol 121 2003 874-885
27. H. Glucksberg R. Storb A. Fefer et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors Transplantation 18 1974 295-304
28. H.M. Shulman K.M. Sullivan P.L. Weiden et al. Chronic graft-versus-host syndrome in man: A long-term clinicopathologic study of 20 Seattle patients Am J Med 69 1980 204-217
29. M.L. Slovak K.J. Kopecky P.A. Cassileth et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: A Southwest Oncology Group/Eastern Cooperative Oncology Group study Blood 96 2000 4075-4083
30. A. Urbano-Ispizua E. Carreras P. Marin et al. Allogeneic transplantation of CD34(+) selected cells from peripheral blood from human leukocyte antigen-identical siblings: Detrimental effect of a high number of donor CD34(+) cells? Blood 98 2001 2352-2357
31. M. Mohty K. Bilger E. Jourdan et al. Higher doses of CD34+ peripheral blood stem cells are associated with increased mortality from chronic graft-versus-host disease after allogeneic HLA-identical sibling transplantation Leukemia 17 2003 869-875